Evaluating GLP-1 Telehealth: What Physicians Should Know

The Rise of GLP-1 Telehealth Scoring Systems

The proliferation of GLP-1 receptor agonist telehealth services has created a vetting challenge for physicians and patients alike. A new independent ranking framework attempts to standardize quality metrics across providers offering semaglutide, tirzepatide, and related compounds. Understanding what these scores measure—and what they miss—matters for clinical decision-making.

What Independent Rankings Actually Assess

These scoring systems typically evaluate:

• Baseline metabolic testing: Whether providers mandate fasting glucose, HbA1c, lipid panels, and renal function before initiating therapy
• Thyroid surveillance: TSH, free T4, and in some cases reverse T3 monitoring (critical for GLP-1 users, as these agents can affect thyroid function)
• Cardiovascular risk stratification: Blood pressure, ECG when indicated, lipid response tracking
• Provider credentials: Board certification, prescribing scope, availability for dose adjustment
• Adverse event protocols: Documented procedures for pancreatitis, thyroid concerns, or gastrointestinal complications

What they don't reliably measure: actual clinical outcomes, patient adherence rates, or long-term metabolic recovery post-therapy.

Critical Lab Baselines Before GLP-1 Initiation

Any credible GLP-1 program should require:

Glucose metabolism:

• Fasting glucose
• HbA1c (target <5.7% for non-diabetic users, establishes baseline)
• Insulin and C-peptide (defines insulin sensitivity at baseline)

Lipid and metabolic panel:

• Total cholesterol, LDL, HDL, triglycerides
• ALT, AST (liver function)
• Creatinine and eGFR (renal function—critical for dose adjustment)

Thyroid axis:

• TSH, free T4
• Thyroid peroxidase antibodies (TPO) if family history of autoimmune thyroiditis

Hormonal baseline:

• Total and free testosterone (GLP-1 can suppress appetite-driven caloric intake, affecting SHBG and hormone metabolism)
• DHEA-S, cortisol (stress response)
• For women: estradiol and progesterone if menstruating

Gastrointestinal and pancreatic:

• Lipase, amylase (pancreatitis risk is real, though rare)
• Calcitonin if family history of medullary thyroid carcinoma

How GLP-1 Agonists Alter Endocrine Function

GLP-1 receptor agonists don't just suppress appetite—they reshape hormonal signaling:

Growth hormone and IGF-1: Caloric restriction induced by GLP-1 can suppress IGF-1 by 15-30%, mimicking energy deficit. This is reversible but relevant for patients on concurrent peptide therapies (GHRP-2, ipamorelin, sermorelin).

Testosterone: Rapid weight loss can temporarily suppress free testosterone by downregulating SHBG. Baseline testosterone <400 ng/dL + GLP-1 use may warrant monitoring at 8-12 weeks.

Thyroid: GLP-1 slows gastric emptying, which can reduce iodine absorption. TSH can rise 10-20% in susceptible individuals. Serial TSH at 6, 12, and 24 weeks is standard practice.

Cortisol: Weight loss stress can elevate morning cortisol. If baseline cortisol is already elevated (>20 mcg/dL), GLP-1 + high-intensity training may compound fatigue.

Synergistic Supplementation During GLP-1 Therapy

The catabolic state induced by GLP-1 accelerates micronutrient depletion. Evidence-based cofactors:

Magnesium glycinate (400-500 mg/day): Restores intracellular magnesium lost in caloric deficit, supports muscle protein synthesis. GLP-1 impairs gastric emptying; glycinate form enhances absorption.

Zinc (25-30 mg/day, elemental): Supports thyroid peroxidase function and testosterone synthesis. GLP-1-induced weight loss can drop zinc by 8-12%.

Vitamin D3 + K2 (4,000 IU + 180 mcg MK-7/day): Caloric restriction reduces vitamin D synthesis. Concurrent GLP-1 increases fracture risk if vitamin D <30 ng/mL baseline.

Creatine monohydrate (5 g/day): Preserves lean mass during rapid weight loss. GLP-1 users losing >1.5 lbs/week benefit from creatine's anti-catabolic effect.

NAC (1,200-1,800 mg/day): Supports glutathione synthesis; GLP-1-induced rapid weight loss creates oxidative stress.

Collagen peptides (20-30 g/day, hydrolyzed): Provides glycine and proline for muscle and connective tissue preservation. GLP-1 + collagen preserves bone density better than GLP-1 alone.

Ashwagandha (600 mg/day, standardized to 5% withanolides): Buffers stress-induced cortisol elevation that can blunt weight loss efficacy.

Reading Your Labs: The Physician's Checklist

IGF-1: Normal range 80-190 ng/mL. On GLP-1, expect 15-30% decline. If below 50 ng/mL, consider GHRP-2 or sermorelin co-therapy to preserve lean mass.

Testosterone (total): Men should maintain >400 ng/dL. On GLP-1, monitor every 12 weeks. If trending below 350 ng/dL, assess SHBG (may be artificially low due to rapid fat loss); consider testosterone replacement if baseline was low-normal.

TSH: Target <2.5 mIU/L on GLP-1. If TSH rises above 4.0, measure free T4 and TPO; consider levothyroxine 25-50 mcg if clinically indicated.

HbA1c and fasting glucose: Track every 12 weeks. GLP-1 users often see HbA1c drop by 1-2% in first 8 weeks. Risk: overtreatment if concurrent metformin or sulfonylureas; adjust dosing.

Creatinine and eGFR: GLP-1 slows renal perfusion slightly. If eGFR drops below 60, reduce dose or extend dosing intervals. Baseline <30 mL/min/1.73m² is a contraindication.

Quality Scoring: What to Demand

When evaluating a telehealth GLP-1 provider:

1. Do they require baseline labs before prescribing? (Non-negotiable.)
2. Is serial monitoring built in? (Minimum: 4-week, 8-week, 12-week checkpoints.)
3. Can they manage dose titration without requiring in-person visits?
4. Do they screen for contraindications (pancreatitis history, medullary thyroid carcinoma family history)?
5. Are they networked with a pharmacy that verifies pharmaceutical-grade supply?

Independent ranking systems help. But physician judgment—especially knowledge of GLP-1's endocrine effects—remains essential.

Bottom Line

GLP-1 telehealth services are clinically legitimate when they enforce baseline testing, understand the hormonal cascade they trigger, and commit to serial monitoring. The absence of these standards signals a provider optimizing for speed, not outcomes. Evaluate the framework, not just the ranking score.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.